News Novo Nordisk cuts GLP-1 prices for cash buyers Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.
News Under pressure from Trump, Lilly hikes Mounjaro prices in UK Lilly has said it will raise the UK list price of its diabetes and obesity therapy Mounjaro to bring it into parity with other European markets.
News Lilly-backed scheme aims to help UK improve obesity care Tens of thousands of NHS patients living with obesity could get help to reduce their weight through a partnership between the UK and Eli Lilly.
News Apple partners with FuturHealth on weight loss An alliance between Apple and FuturHealth will combine GLP-1 weight-loss treatment with the tech giant's Fitness+ subscription.
News Lilly weakens on oral weight-loss drug data Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.
News Novo Nordisk weakens again on interim results readout Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
